ID: ALA214540

Max Phase: Preclinical

Molecular Formula: C15H17NaO4

Molecular Weight: 262.30

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(C(=O)[O-])c2c1CC1(CCCCC1)O2.[Na+]

Standard InChI:  InChI=1S/C15H18O4.Na/c1-18-12-6-5-10(14(16)17)13-11(12)9-15(19-13)7-3-2-4-8-15;/h5-6H,2-4,7-9H2,1H3,(H,16,17);/q;+1/p-1

Standard InChI Key:  IJHDZMSPUUYSFF-UHFFFAOYSA-M

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 262.30Molecular Weight (Monoisotopic): 262.1205AlogP: 3.03#Rotatable Bonds: 2
Polar Surface Area: 55.76Molecular Species: ACIDHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 4.00CX Basic pKa: CX LogP: 3.08CX LogD: -0.08
Aromatic Rings: 1Heavy Atoms: 19QED Weighted: 0.89Np Likeness Score: 0.64

References

1. Useglio M, Castellano PM, Operto MA, Torres R, Kaufman TS..  (2006)  Synthesis of 3H-spiro[benzofuran-2,1'-cyclohexane] derivatives from naturally occurring filifolinol and their classical complement pathway inhibitory activity.,  16  (19): [PMID:16875818] [10.1016/j.bmcl.2006.07.029]

Source